Chapter 2. Antimicrobial Resistance
Abattoir Surveillance
Key Findings
Beef Cattle
Escherichia Coli (n = 165)
One percent (1/165) of E. coli isolates were resistant to nalidixic acid (Table 26). The previous occurrence of this resistance in CIPARS Abattoir surveillance was 1 isolate (less than 1%, 1/167) in 2004 (Figure 15).
Campylobacter (n = 152)
Recovery of Campylobacter isolates in beef continues to rise from 77% (108/141) in 2011 to 92% (152/166) in 2012 (Table 42).
Slight increase in resistance to ciprofloxacin was observed from 2011 (1%, 1/108) to 2012 (5%, 8/152) (Figure 16).
Resistance to tetracycline was significantly higher in 2012 (63%, 95/152) than in 2006 (45%, 37/82) (Figure 16).
Chickens
Salmonella (n = 126)
Recovery of Salmonella in chickens continued to decline to 18% (126/684) from a peak of 28% (234/851) in 2008 (Table 42). This is similar to levels from the first 3 years of the program (2003-2005).
The proportion of S. Enteritidis isolates decreased from 20% (28/140) in 2011 to 7% (7/104), although 22 isolates do not have serovar information in the 2012 data.
In 2012, resistance to ceftiofur (20%, 25/126) and ampicillin (24%, 30/126) was significantly lower than in 2011 (31%, 44/140; 36%, 51/140, respectively) (Figure 17). This difference was primarily driven by a decrease in ceftiofur (2012: 26%, 11/43; 2011: 57%, 33/58) and ampicillin resistance (2012: 28%, 12/43; 2011: 57% 33/58) in Kentucky isolates.
Resistance to ceftiofur was significantly higher (20%, 25/126) in 2012 than in 2006 (10%, 18/187) (Figure 17).
Resistance to streptomycin and tetracycline was significantly higher in 2012 (39%, 49/126, 40%, 51/126, respectively) than in 2003 (24%, 30/126, 19%, 24/126, respectively) (Figure 17).
Escherichia Coli (n = 173)
Two percent of E. coli isolates (3/173) were resistant to 6 to 7 classes of antimicrobials (Table 29). The previous occurrence of this multi-class resistance in CIPARS Abattoir Surveillance was 2 isolates (2/171) in 2009.
The apparent slow increase in resistance to nalidixic acid in 2011 (5%, 9/164) continued in 2012 (8%, 14/173) (Figure 18). One percent (1/173) of isolates were resistant to ciprofloxacin (Table 29 and Table 37). This is the first time resistance to ciprofloxacin has been observed in E. coli isolates from abattoir chicken.
Other key findings were:
- One percent (1/173) of isolates were resistant to azithromycin (Table 29 and Table 37).
- The decrease in resistance to ceftiofur seen in 2011 (20%, 32/164) was maintained in 2012 (17%, 30/173) (Figure 18).
- Resistance to tetracycline was significantly lower in 2012 (51%, 88/173) than in 2003 (69%, 106/153) (Figure 18).
- Resistance to trimethoprim-sulfamethoxazole was significantly higher (15%, 26/173) in 2012 than in 2003 (8%, 12/153) (Figure 18).
Campylobacter (n = 155)
One percent (2/145) of C. jejuni isolates was resistant to 4 to 5 classes of antimicrobials (Table 30). Although this has been previously seen in C. coli from CIPARS Abattoir Surveillance, this is the first occurrence in C. jejuni. The number of C. coli isolates susceptible to all of the classes of antimicrobials tested decreased from 11 (out of 13) in 2011 to 3 (out of 10) in 2012.
Pigs
Salmonella (n = 157)
Resistance to trimethoprim-sulfamethoxazole was significantly higher in 2012 (6%, 9/157) than in 2003 (2%, 9/391) (Figure 20).
Escherichia Coli (n = 184)
Resistance to streptomycin and tetracycline was significantly higher in 2012 (40%, 73/184; 84%, 154/184, respectively) than in 2011 (30%, 57/190; 75%, 143/190, respectively) (Figure 21).
Campylobacter (n = 287)
No temporal analysis and temporal figure were presented in this report as 2012 is the first year where surveillance began. Recovery of Campylobacter in the first year of porcine sampling was 78% (289/370) (Table 42). Ninety-nine percent (286/287) of isolates were C. coli, less than 1% (1/287) were Campylobacter spp., and no C. jejuni were isolated. Other key findings were:
- Approximately 45% of isolates were resistant to telithromycin (128/287) and clindamycin (126/287) (Table 33 and Table 41).
- Fifty-three percent (151/287) of isolates were resistant to azithromycin and erythromycin (Table 33 and Table 41).
- Ten percent of isolates were resistant to ciprofloxacin (28/287) and nalidixic acid (29/287) (Table 33 and Table 41).
The high proportion (99%) of C. coli plays a role in the percentage of isolates resistant to these antimicrobials.
Multiclass Resistance
| Animal species | Number (%) of isolates | Number of isolates by number of antimicrobial classes in the resistance pattern | Number of isolates resistant by antimicrobial class and antimicrobial | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aminoglycosides | β-lactams | Folate pathway inhibitors | Macrolides | Phenicols | Quinolones | Tetracyclines | |||||||||||||||
| 0 | 1 | 2-3 | 4-5 | 6-7 | GEN | KAN | STR | AMP | AMC | CRO | FOX | TIO | SSS | SXT | AZM | CHL | CIP | NAL | TET | ||
| Beef cattle | 165 | 113 | 32 | 19 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | 17 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 45 | ||||||||
Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance in human medicine, respectively.
| Species | Number (%) of isolates | Number of isolates by number of antimicrobial classes in the resistance pattern | Number of isolates resistant by antimicrobial class and antimicrobial | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aminoglycosides | Ketolides lactams | Lincosamides | Macrolides | Phenicols | Quinolones | Tetracyclines | |||||||||
| 0 | 1 | 2-3 | 4-5 | 6-7 | GEN | TEL | CLI | AZM | ERY | FLR | CIP | NAL | TET | ||
| Campylobacter jejuni | 111 (73.0) | 47 | 58 | 6 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 | 64 | ||||||||
| Campylobacter coli | 39 (25.7) | 7 | 30 | 2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | 32 | ||||||||
| Campylobacter spp. | 2 (1.3) | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | ||||||||||||
| Total | 152 (100) | 54 | 90 | 8 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 | 96 | ||||||||
Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance in human medicine, respectively.
Campylobacter spp. include unidentified species, some of which may be intrinsically resistant to nalidixic acid.
| Serovar | Number (%) of isolates | Number of isolates by number of antimicrobial classes in the resistance pattern | Number of isolates resistant by antimicrobial class and antimicrobial | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aminoglycosides | β-lactams | Folate pathway inhibitors | Macrolides | Phenicols | Quinolones | Tetracyclines | |||||||||||||||
| 0 | 1 | 2-3 | 4-5 | 6-7 | GEN | KAN | STR | AMP | AMC | CRO | FOX | TIO | SSS | SXT | AZM | CHL | CIP | NAL | TET | ||
| Kentucky | 43 (41.3) | 9 | 3 | 31 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.11 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.11 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.11 | 31 | |||||||||
| Heidelberg | 26 (25) | 18 | 7 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 1 | 1 | ||||||||
| Hadar | 8 (7.7) | 4 | 4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 4 | |||||||||||||||
| Enteritidis | 7 (6.7) | 7 | |||||||||||||||||||
| Schwarzengrund | 4 (3.8) | 4 | |||||||||||||||||||
| Thompson | 4 (3.8) | 3 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 1 | |||||||||||||||
| Less common serovars | 12 (11.5) | 7 | 2 | 2 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | 3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 1 | 4 | ||||||
| Total | 104 (100) | 52 | 12 | 39 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.38 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.19 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.19 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.19 | 5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | 2 | 40 | |||||
Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance to human medicine, respectively.
Serovars represented by less than 2% of isolates were classified as "Less common serovars".
The total number of isolates was 126 but 22 isolates did not have serovar information.
| Animal species | Number (%) of isolates | Number of isolates by number of antimicrobial classes in the resistance pattern | Number of isolates resistant by antimicrobial class and antimicrobial | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aminoglycosides | β-lactams | Folate pathway inhibitors | Macrolides | Phenicols | Quinolones | Tetracyclines | |||||||||||||||
| 0 | 1 | 2-3 | 4-5 | 6-7 | GEN | KAN | STR | AMP | AMC | CRO | FOX | TIO | SSS | SXT | AZM | CHL | CIP | NAL | TET | ||
| Chickens | 173 | 48 | 24 | 70 | 28 | 3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.23 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.87 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.33 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.32 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.30 | 70 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 9 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14 | 88 |
Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance to human medicine, respectively.
| Species | Number (%) of isolates | Number of isolates by number of antimicrobial classes in the resistance pattern | Number of isolates resistant by antimicrobial class and antimicrobial | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aminoglycosides | Ketolides lactams | Lincosamides | Macrolides | Phenicols | Quinolones | Tetracyclines | |||||||||
| 0 | 1 | 2-3 | 4-5 | 6-7 | GEN | TEL | CLI | AZM | ERY | FLR | CIP | NAL | TET | ||
| Campylobacter jejuni | 145 (93.5) | 71 | 58 | 14 | 2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 | 70 | |||
| Campylobacter coli | 10 (6.5) | 3 | 6 | 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | 6 | ||||
| Total | 155 (100) | 74 | 64 | 14 | 3 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.11 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 | 76 | |||
Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance in human medicine, respectively.
| Serovar | Number (%) of isolates | Number of isolates by number of antimicrobial classes in the resistance pattern | Number of isolates resistant by antimicrobial class and antimicrobial | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aminoglycosides | β-lactams | Folate pathway inhibitors | Macrolides | Phenicols | Quinolones | Tetracyclines | |||||||||||||||
| 0 | 1 | 2-3 | 4-5 | 6-7 | GEN | KAN | STR | AMP | AMC | CRO | FOX | TIO | SSS | SXT | AZM | CHL | CIP | NAL | TET | ||
| Derby | 36 (24.2) | 5 | 9 | 22 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21 | 22 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | 3 | 26 | ||||||||||
| Typhimurium var. 5- | 18 (12.1) | 1 | 6 | 11 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14 | 17 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | 10 | 13 | ||||||||||
| Infantis | 16 (10.7) | 15 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | |||||||||||||
| Brandenburg | 10 (6.7) | 5 | 3 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | 3 | |||||||||||||
| London | 10 (6.7) | 9 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 1 | 1 | ||||||||||||||
| Agona | 8 (5.4) | 5 | 2 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 1 | 3 | ||||||||
| Typhimurium | 8 (5.4) | 3 | 1 | 4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 | 4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 3 | 5 | |||||||||
| Bovismorbificans | 6 (4.0) | 3 | 3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | 3 | 3 | ||||||||||||||
| Give | 4 (2.7) | 4 | |||||||||||||||||||
| 4,[5],12:i:- | 4 (2.7) | 1 | 1 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | 2 | 3 | |||||||||||||
| Muenchen | 4 (2.7) | 4 | |||||||||||||||||||
| Ohio | 4 (2.7) | 3 | 1 | 1 | |||||||||||||||||
| Worthington | 4 (2.7) | 4 | |||||||||||||||||||
| Putten | 3 (2.0) | 3 | |||||||||||||||||||
| Less common serovars | 14 (9.4) | 7 | 3 | 4 | 2 | 4 | 2 | 1 | 1 | 1 | 1 | 2 | 7 | ||||||||
| Total | 149 (100) | 72 | 20 | 35 | 22 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 | 52 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 17 | 65 | |||
Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance to human medicine, respectively.
Serovars represented by less than 2% of isolates were classified as "Less common serovars".
The total number of isolates was 157 but 8 isolates did not have serovar information.
| Animal species | Number (%) of isolates | Number of isolates by number of antimicrobial classes in the resistance pattern | Number of isolates resistant by antimicrobial class and antimicrobial | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aminoglycosides | β-lactams | Folate pathway inhibitors | Macrolides | Phenicols | Quinolones | Tetracyclines | |||||||||||||||
| 0 | 1 | 2-3 | 4-5 | 6-7 | GEN | KAN | STR | AMP | AMC | CRO | FOX | TIO | SSS | SXT | AZM | CHL | CIP | NAL | TET | ||
| Pigs | 184 | 20 | 40 | 89 | 35 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 | 72 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 34 | 154 | |||
Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance to human medicine, respectively.
| Species | Number (%) of isolates | Number of isolates by number of antimicrobial classes in the resistance pattern | Number of isolates resistant by antimicrobial class and antimicrobial | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aminoglycosides | Ketolides lactams | Lincosamides | Macrolides | Phenicols | Quinolones | Tetracyclines | |||||||||
| 0 | 1 | 2-3 | 4-5 | 6-7 | GEN | TEL | CLI | AZM | ERY | FLR | CIP | NAL | TET | ||
| Campylobacter coli | 286 (99.7) | 44 | 69 | 81 | 92 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.128 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.126 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.151 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.151 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.28 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28 | 216 | |||
| Campylobacter spp. | 1 (0.3) | 1 | 1 | 1 | |||||||||||
| Total | 287 (100) | 44 | 69 | 82 | 92 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.128 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.126 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.151 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.151 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.28 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29 | 217 | |||
Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance in human medicine, respectively.
Campylobacter spp. include unidentified species, some of which may be intrinsically resistant to nalidixic acid.
Temporal Antimicrobial Resistance Summary
Figure 15. Temporal variations in resistance of Escherichia coli isolates from beef cattle
| Year | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of isolates | 153 | 167 | 122 | 150 | 188 | 176 | 119 | 77 | 139 | 165 |
| Antimicrobial | ||||||||||
| Ampicillin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% | 7% | 2% | 5% | 3% | 1% | 2% | 1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% |
| Ceftiofur | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | 1% | 0% | 0% | 0% | 0% | 0% | 0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% |
| Gentamicin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | 1% | 0% | 0% | 1% | 0% | 3% | 0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% |
| Nalidixic acid | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | 1% | 0% | 0% | 0% | 0% | 0% | 0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% |
| Streptomycin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.14% | 10% | 8% | 9% | 12% | 15% | 18% | 5% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7% |
| Tetracycline | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.29% | 25% | 22% | 30% | 36% | 38% | 30% | 14% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.28% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.27% |
| Trimethoprim-sulfamethoxazole | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | 1% | 0% | 1% | 0% | 0% | 1% | 0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% |
For the temporal analyses, the proportion (%) of isolates resistant to a specific antimicrobial over the current year has been compared to the proportion (%) of isolates resistant to the same antimicrobial during the first and the previous surveillance year (grey areas). |
||||||||||
Figure 16. Temporal variations in resistance of Campylobacter isolates from beef cattle
| Year | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 |
|---|---|---|---|---|---|---|---|
| Number of isolates | 105a | 73 | 128 | 86 | 37 | 108 | 152 |
| Antimicrobial | |||||||
| Azithromycin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | 0% | 0% | 0% | 0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% |
| Ciprofloxacin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | 1% | 2% | 1% | 3% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5% |
| Gentamicin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | 0% | 0% | 0% | 0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% |
| Telithromycin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | 0% | 0% | 0% | 0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% |
| Tetracycline | Significant differences (P ≤ 0.05) for a given antimicrobial.46% | 66% | 66% | 52% | 51% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.57% | Significant differences (P ≤ 0.05) for a given antimicrobial.63% |
For the temporal analyses, the proportion (%) of isolates resistant to a specific antimicrobial over the current year has been compared to the proportion (%) of isolates resistant to the same antimicrobial during the first and the previous surveillance year (grey areas). The presence of blue areas indicates significant differences (P ≤ 0.05) for a given antimicrobial. |
|||||||
Figure 17. Temporal variations in resistance of Salmonella isolates from chickens
| Year | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of isolates | 126 | 142 | 199 | 187 | 206 | 234 | 230 | 142 | 140 | 126 |
| Antimicrobial | ||||||||||
| Ampicillin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.25% | 27% | 18% | 16% | 18% | 16% | 31% | 37% | Significant differences (P ≤ 0.05) for a given antimicrobial.36% | Significant differences (P ≤ 0.05) for a given antimicrobial.24% |
| Ceftiofur | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.6% | 22% | 13% | Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.10% | 12% | 12% | 23% | 32% | Significant differences (P ≤ 0.05) for a given antimicrobial.31% | Significant differences (P ≤ 0.05) for a given antimicrobial. Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.20% |
| Gentamicin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5% | 1% | 2% | 2% | 0% | 0% | 1% | 1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% |
| Nalidixic acid | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | 0% | 0% | 0% | 0% | 0% | 0% | 1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% |
| Streptomycin | Significant differences (P ≤ 0.05) for a given antimicrobial.24% | 12% | 14% | 35% | 37% | 40% | 41% | 30% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.44% | Significant differences (P ≤ 0.05) for a given antimicrobial.39% |
| Tetracycline | Significant differences (P ≤ 0.05) for a given antimicrobial.19% | 15% | 21% | 37% | 44% | 41% | 37% | 31% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.44% | Significant differences (P ≤ 0.05) for a given antimicrobial.40% |
| Trimethoprim-sulfamethoxazole | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | 0% | 1% | 1% | 0% | 0% | 0% | 1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% |
For the temporal analyses, the proportion (%) of isolates resistant to a specific antimicrobial over the current year has been compared to the proportion (%) of isolates resistant to the same antimicrobial during the first and the previous surveillance year (grey areas). The presence of blue areas indicates significant differences (P ≤ 0.05) for a given and antimicrobial. |
||||||||||
Figure 18. Temporal variations in resistance of Escherichia coli isolates from chickens
| Year | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of isolates | 153 | 131 | 220 | 167 | 180 | 170 | 171 | 119 | 164 | 173 |
| Antimicrobial | ||||||||||
| Ampicillin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.41% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.43% | 38% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.43% | 39% | 36% | 43% | 53% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.40% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.39% |
| Ceftiofur | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.17% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.25% | 20% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.21% | 26% | 20% | 29% | 34% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.20% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.17% |
| Gentamicin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.15% | 11% | 11% | 8% | 11% | 8% | 12% | 10% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.13% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.13% |
| Nalidixic acid | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% | 3% | 5% | 4% | 2% | 4% | 5% | 4% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.8% |
| Streptomycin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.52% | 53% | 43% | 34% | 40% | 44% | 45% | 50% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.50% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.50% |
| Tetracycline | Significant differences (P ≤ 0.05) for a given antimicrobial.69% | 56% | 58% | 51% | 57% | 51% | 44% | 52% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.52% | Significant differences (P ≤ 0.05) for a given antimicrobial.51% |
| Trimethoprim-sulfamethoxazole | Significant differences (P ≤ 0.05) for a given antimicrobial.8% | 11% | 9% | 10% | 4% | 12% | 9% | 10% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.15% | Significant differences (P ≤ 0.05) for a given antimicrobial.15% |
For the temporal analyses, the proportion (%) of isolates resistant to a specific antimicrobial over the current year has been compared to the proportion (%) of isolates resistant to the same antimicrobial during the first and the previous surveillance year (grey areas). The presence of blue areas indicates significant differences (P ≤ 0.05) for a given and antimicrobial. |
||||||||||
Figure 19. Temporal variations in resistance of Campylobacter isolates from chickens
| Year | 2010 | 2011 | 2012 |
|---|---|---|---|
| Number of isolates | 111 | 117 | 155 |
| Antimicrobial | |||
| Azithromycin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.6% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.6% |
| Ciprofloxacin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7% |
| Gentamicin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% |
| Telithromycin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5% |
| Tetracycline | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.47% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.39% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.49% |
For the temporal analyses, the proportion (%) of isolates resistant to a specific antimicrobial over the current year has been compared to the proportion (%) of isolates resistant to the same antimicrobial during the first and the previous surveillance year (grey areas). |
|||
Figure 20. Temporal variations in resistance of Salmonella isolates from pigs
| Year | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of isolates | 391 | 269 | 212 | 145 | 105 | 151 | 147 | 182 | 165 | 157 |
| Antimicrobial | ||||||||||
| Ampicillin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.18% | 13% | 13% | 19% | 29% | 28% | 20% | 24% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.21% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.22% |
| Ceftiofur | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | 0% | 0% | 1% | 1% | 1% | 0% | 3% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% |
| Gentamicin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% | 2% | 0% | 1% | 6% | 1% | 1% | 2% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% |
| Nalidixic acid | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% |
| Streptomycin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.34% | 26% | 30% | 30% | 45% | 44% | 39% | 37% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.38% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.36% |
| Tetracycline | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.45% | 42% | 44% | 48% | 55% | 58% | 46% | 48% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.48% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.45% |
| Trimethoprim-sulfamethoxazole | Significant differences (P ≤ 0.05) for a given antimicrobial.2% | 5% | 2% | 6% | 6% | 7% | 3% | 6% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% | Significant differences (P ≤ 0.05) for a given antimicrobial.6% |
For the temporal analyses, the proportion (%) of isolates resistant to a specific antimicrobial over the current year has been compared to the proportion (%) of isolates resistant to the same antimicrobial during the first and the previous surveillance year (grey areas). The presence of blue areas indicates significant differences (P ≤ 0.05) for a given and antimicrobial. |
||||||||||
Figure 21. Temporal variations in resistance of Escherichia coli isolates from pigs
| Year | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of isolates | 153 | 142 | 163 | 114 | 93 | 150 | 160 | 199 | 190 | 184 |
| Antimicrobial | ||||||||||
| Ampicillin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.35% | 30% | 35% | 35% | 37% | 33% | 33% | 37% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.37% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.36% |
| Ceftiofur | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | 0% | 1% | 0% | 1% | 1% | 1% | 2% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% |
| Gentamicin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% | 1% | 1% | 2% | 0% | 2% | 2% | 0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% |
| Nalidixic acid | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | 0% | 1% | 0% | 0% | 1% | 0% | 0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% |
| Streptomycin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.40% | 39% | 39% | 26% | 33% | 35% | 47% | 36% | Significant differences (P ≤ 0.05) for a given antimicrobial.30% | Significant differences (P ≤ 0.05) for a given antimicrobial.40% |
| Tetracycline | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.82% | 71% | 75% | 83% | 75% | 85% | 77% | 72% | Significant differences (P ≤ 0.05) for a given antimicrobial.75% | Significant differences (P ≤ 0.05) for a given antimicrobial.84% |
| Trimethoprim-sulfamethoxazole | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.14% | 5% | 10% | 18% | 12% | 13% | 12% | 14% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.12% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.14% |
For the temporal analyses, the proportion (%) of isolates resistant to a specific antimicrobial over the current year has been compared to the proportion (%) of isolates resistant to the same antimicrobial during the first and the previous surveillance year (grey areas). The presence of blue areas indicates significant differences (P ≤ 0.05) for a given and antimicrobial. |
||||||||||
Minimum Inhibitory Concentrations
More details on how to interpret the minimum inhibitory concentrations (MICs) tables are provided in the CIPARS Annual Report 2012 – Chapter 1. Design and Methods.
| Antimicrobial | n | Percentiles | % R | Distribution (%) of MICs (µg/mL) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC 50 | MIC 90 | ≤ 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | >256 | ||||
| I | Amoxicillin-clavulanic acid | 165 | 4 | 4 | 0.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.8 Table 34 - Footnote1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.6 Table 34 - Footnote2 | |||||||||||
| Ceftiofur | 165 | 0.25 | 0.50 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | Table 34 - Footnote1 | Table 34 - Footnote2 | |||||||||||
| Ceftriaxone | 165 | ≤ 0.25 | ≤ 0.25 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.99.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | Table 34 - Footnote1 | Table 34 - Footnote2 | |||||||||||||
| Ciprofloxacin | 165 | ≤ 0.015 | ≤ 0.015 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.98.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | Table 34 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | Table 34 - Footnote2 | ||||||||||||
| II | Ampicillin | 165 | 2 | 4 | 0.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28.5 | Table 34 - Footnote1 | Table 34 - Footnote2 | 0.6 | ||||||||||
| Azithromycin | 165 | 4 | 4 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.5 | Table 34 - Footnote2 | ||||||||||||
| Cefoxitin | 165 | 4 | 8 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.62.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.7 Table 34 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 | Table 34 - Footnote2 | |||||||||||
| Gentamicin | 165 | 1 | 1 | 1.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.74.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.1 | Table 34 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.2 | ||||||||||
| Kanamycin | 165 | ≤ 8 | ≤ 8 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 Table 34 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.8 | Table 34 - Footnote2 | |||||||||||||
| Nalidixic acid | 165 | 2 | 4 | 0.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.2 | Table 34 - Footnote2 | 0.6 | ||||||||||||
| Streptomycin | 165 | ≤ 32 | ≤ 32 | 7.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.92.7 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.2 Table 34 - Footnote2 | 3.0 | ||||||||||||||
| Trimethoprim-sulfamethoxazole | 165 | ≤ 0.12 | ≤ 0.12 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.98.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | Table 34 - Footnote2 | |||||||||||||
| III | Chloramphenicol | 165 | 8 | 8 | 0.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.58.8 Table 34 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 | Table 34 - Footnote2 | 0.6 | ||||||||||
| Sulfisoxazole | 165 | ≤ 16 | > 256 | 10.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.8 | 10.3 Table 34 - Footnote2 | |||||||||||||
| Tetracycline | 165 | ≤ 4 | > 32 | 27.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66.1 Table 34 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.7 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.5 Table 34 - Footnote2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.4 | 19.4 | ||||||||||||
| IV | |||||||||||||||||||||
| Antimicrobial | Species | n | Percentiles | % R | Distribution (%) of MICs (µg/mL) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC 50 | MIC 90 | ≤ 0.016 | 0.032 | 0.064 | 0.125 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | >64 | |||||
| I | Ciprofloxacin | Campylobacter coli | 39 | 0.125 | 0.25 | 5.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28.2 | Table 35 - Footnote1 | Table 35 - Footnote2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.6 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.6 | ||||||||
| Ciprofloxacin | Campylobacter jejuni | 111 | 0.125 | 0.25 | 5.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 | Table 35 - Footnote1 | Table 35 - Footnote2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.7 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.9 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.8 | ||||||
| Ciprofloxacin | Campylobacter spp. | 2 | 0.25 | 0.25 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0 | Table 35 - Footnote1 | Table 35 - Footnote2 | ||||||||||||
| Telithromycin | Campylobacter coli | 39 | 4 | 4 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.35.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.61.5 Table 35 - Footnote1 | Table 35 - Footnote2 | |||||||||||
| Telithromycin | Campylobacter jejuni | 111 | 1 | 2 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.6 | Table 35 - Footnote1 | Table 35 - Footnote2 | |||||||||
| Telithromycin | Campylobacter spp. | 2 | 1 | 1 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 | Table 35 - Footnote1 | Table 35 - Footnote2 | |||||||||||
| II | Azithromycin | Campylobacter coli | 39 | 0.125 | 0.25 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.69.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30.8 | Table 35 - Footnote1 | Table 35 - Footnote2 | 52.8 | |||||||||
| Azithromycin | Campylobacter jejuni | 111 | 0.064 | 0.064 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.41.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.51.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.2 | Table 35 - Footnote1 | Table 35 - Footnote2 | ||||||||||
| Azithromycin | Campylobacter spp. | 2 | 0.25 | 0.25 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 | Table 35 - Footnote1 | Table 35 - Footnote2 | |||||||||||
| Clindamycin | Campylobacter coli | 39 | 0.5 | 1 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.51.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43.6 | Table 35 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6 | Table 35 - Footnote2 | |||||||||
| Clindamycin | Campylobacter jejuni | 111 | 0.25 | 0.25 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.32.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.59.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.6 | Table 35 - Footnote1 | Table 35 - Footnote2 | ||||||||
| Clindamycin | Campylobacter spp. | 2 | 0.25 | 0.25 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 | Table 35 - Footnote1 | Table 35 - Footnote2 | |||||||||||
| Erythromycin | Campylobacter coli | 39 | 2 | 2 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.79.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.7 | Table 35 - Footnote2 | |||||||||||
| Erythromycin | Campylobacter jejuni | 111 | 0.5 | 0.5 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.55.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.0 | Table 35 - Footnote2 | ||||||||||
| Erythromycin | Campylobacter spp. | 2 | 0.5 | 0.5 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0 | Table 35 - Footnote2 | |||||||||||||
| Gentamicin | Campylobacter coli | 39 | 1 | 1 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.84.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6 Table 35 - Footnote1 | Table 35 - Footnote2 | |||||||||||
| Gentamicin | Campylobacter jejuni | 111 | 1 | 2 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.76.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.7 Table 35 - Footnote1 | Table 35 - Footnote2 | |||||||||||
| Gentamicin | Campylobacter spp. | 2 | 0.25 | 0.25 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0 | Table 35 - Footnote1 | Table 35 - Footnote2 | ||||||||||||
| Nalidixic acid | Campylobacter coli | 39 | 16 | 16 | 5.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.38.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.56.4 Table 35 - Footnote1 | Table 35 - Footnote2 | 5.4 | |||||||||||
| Nalidixic acid | Campylobacter jejuni | 111 | ≤ 4 | 8 | 5.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.41.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 Table 35 - Footnote1 | Table 35 - Footnote2 | 5.4 | ||||||||||
| Nalidixic acid | Campylobacter spp. | 2 | 64 | 64 | 100.0 | Table 35 - Footnote1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.100.0 Table 35 - Footnote2 | |||||||||||||
| III | Florfenicol | Campylobacter coli | 39 | 2 | 2 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71.8 | Table 35 - Footnote1 | |||||||||||
| Florfenicol | Campylobacter jejuni | 111 | 1 | 1 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.84.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.9 | Table 35 - Footnote1 | |||||||||||
| Florfenicol | Campylobacter spp. | 2 | 0.5 | 0.5 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 | Table 35 - Footnote1 | ||||||||||||
| Tetracycline | Campylobacter coli | 39 | > 64 | > 64 | 82.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.9 | Table 35 - Footnote1 | Table 35 - Footnote2 | 82.1 | |||||||||||
| Tetracycline | Campylobacter jejuni | 111 | 32 | > 64 | 57.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.22.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.6 | Table 35 - Footnote1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.9 Table 35 - Footnote2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.18.9 | 30.6 | ||||||
| Tetracycline | Campylobacter spp. | 2 | 0.25 | 0.25 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0 | Table 35 - Footnote1 | Table 35 - Footnote2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.100.0 | |||||||||||
| IV | ||||||||||||||||||||
Campylobacter spp. include unidentified species, some of which may be intrinsically resistant to nalidixic acid.
| Antimicrobial | n | Percentiles | % R | Distribution (%) of MICs (µg/mL) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC 50 | MIC 90 | ≤ 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | >256 | ||||
| I | Amoxicillin-clavulanic acid | 126 | <=1 | >32 | 19.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.4 Table 36 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.4 Table 36 - Footnote2 | 17.5 | ||||||||||
| Ceftiofur | 126 | 1 | >8 | 19.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.46.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 Table 36 - Footnote1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.8 Table 36 - Footnote2 | 19.0 | ||||||||||||
| Ceftriaxone | 126 | <=0.25 | 16 | 19.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.80.2 | Table 36 - Footnote1 | Table 36 - Footnote2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.15.9 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.0 | ||||||||||||
| Ciprofloxacin | 126 | <=0.015 | 0.03 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.85.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.3 | Table 36 - Footnote1 | Table 36 - Footnote2 | |||||||||||||
| II | Ampicillin | 126 | <=1 | >32 | 23.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.72.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.0 | Table 36 - Footnote1 | Table 36 - Footnote2 | 23.8 | |||||||||||
| Azithromycin | 126 | 4 | 8 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 | Table 36 - Footnote2 | ||||||||||||
| Cefoxitin | 126 | 2 | 32 | 19.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 Table 36 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.17.5 Table 36 - Footnote2 | 1.6 | ||||||||||
| Gentamicin | 126 | 0.50 | 1 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.79.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 | Table 36 - Footnote1 | Table 36 - Footnote2 | |||||||||||
| Kanamycin | 126 | <=8 | <=8 | 0.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.99.2 | Table 36 - Footnote1 | Table 36 - Footnote2 | 0.8 | |||||||||||||
| Nalidixic acid | 126 | 4 | 4 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.61.9 | Table 36 - Footnote2 | |||||||||||||
| Streptomycin | 126 | <=32 | >64 | 38.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.61.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.16.7 Table 36 - Footnote2 | 22.2 | ||||||||||||||
| Trimethoprim-sulfamethoxazole | 126 | <=0.12 | <=0.12 | 1.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.96.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.4 | Table 36 - Footnote2 | 1.6 | |||||||||||||
| III | Chloramphenicol | 126 | 8 | 8 | 1.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.8 Table 36 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 | Table 36 - Footnote2 | 1.6 | ||||||||||
| Sulfisoxazole | 126 | 32 | 64 | 6.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.65.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19.0 | 6.3 Table 36 - Footnote2 | |||||||||||||
| Tetracycline | 126 | <=4 | >32 | 40.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57.9 Table 36 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 | Table 36 - Footnote2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.6 | 38.9 | ||||||||||||
| IV | |||||||||||||||||||||
| Antimicrobial | n | Percentiles | % R | Distribution (%) of MICs (µg/mL) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC 50 | MIC 90 | ≤ 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | >256 | ||||
| I | Amoxicillin-clavulanic acid | 173 | 4 | 32 | 19.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.4 Table 37 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.15.0 Table 37 - Footnote2 | 4.0 | |||||||||
| Ceftiofur | 173 | 0.50 | 8 | 17.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 Table 37 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.12.7 Table 37 - Footnote2 | 4.6 | |||||||||
| Ceftriaxone | 173 | <=0.25 | 16 | 18.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.78.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7 Table 37 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 | Table 37 - Footnote2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6.4 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9.8 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.3 | ||||||||||
| Ciprofloxacin | 173 | <=0.015 | 0.03 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.88.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 | Table 37 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.6 Table 37 - Footnote2 | ||||||||||
| II | Ampicillin | 173 | 4 | >32 | 39.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 Table 37 - Footnote1 | Table 37 - Footnote2 | 39.3 | ||||||||||
| Azithromycin | 173 | 4 | 8 | 0.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 | 0.6 Table 37 - Footnote2 | |||||||||||
| Cefoxitin | 173 | 4 | >32 | 19.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.49.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.2 Table 37 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6.9 Table 37 - Footnote2 | 12.1 | |||||||||||
| Gentamicin | 173 | 1 | >16 | 13.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.61.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.1 | Table 37 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.3 Table 37 - Footnote2 | 11.0 | ||||||||||
| Kanamycin | 173 | <=8 | >64 | 17.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.80.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7 Table 37 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.2 Table 37 - Footnote2 | 16.2 | ||||||||||||
| Nalidixic acid | 173 | 2 | 4 | 8.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.62.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.6 Table 37 - Footnote2 | 7.5 | ||||||||||
| Streptomycin | 173 | 64 | >64 | 50.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.49.7 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.11.6 Table 37 - Footnote2 | 38.7 | ||||||||||||||
| Trimethoprim-sulfamethoxazole | 173 | <=0.12 | >4 | 15.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.74.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | Table 37 - Footnote2 | 15.0 | |||||||||||
| III | Chloramphenicol | 173 | 8 | 8 | 5.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53.2 Table 37 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.9 | Table 37 - Footnote2 | 5.2 | ||||||||||
| Sulfisoxazole | 173 | 32 | >256 | 40.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 | 40.5 Table 37 - Footnote2 | |||||||||||||
| Tetracycline | 173 | >32 | >32 | 50.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.49.1 Table 37 - Footnote1 | Table 37 - Footnote2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.6 | 50.3 | |||||||||||||
| IV | |||||||||||||||||||||
| Antimicrobial | Species | n | Percentiles | % R | Distribution (%) of MICs (µg/mL) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC 50 | MIC 90 | ≤ 0.016 | 0.032 | 0.064 | 0.125 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | >64 | |||||
| I | Ciprofloxacin | Campylobacter coli | 10 | 0.125 | 16 | 20.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.0 | Table 38 - Footnote1 | Table 38 - Footnote2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10.0 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10.0 | |||||||
| Ciprofloxacin | Campylobacter jejuni | 145 | 0.125 | 0.25 | 6.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.51.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 | Table 38 - Footnote1 | Table 38 - Footnote2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.8 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.4 | |||||||
| Telithromycin | Campylobacter coli | 10 | 0.5 | 16 | 10.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30.0 | Table 38 - Footnote1 | 10.0 Table 38 - Footnote2 | ||||||||||
| Telithromycin | Campylobacter jejuni | 145 | 1 | 2 | 4.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 Table 38 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 | 4.1 Table 38 - Footnote2 | |||||||
| II | Azithromycin | Campylobacter coli | 10 | 0.064 | >64 | 10.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.0 | Table 38 - Footnote1 | Table 38 - Footnote2 | 10.0 | |||||||
| Azithromycin | Campylobacter jejuni | 145 | 0.064 | 0.125 | 5.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.52.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.0 | Table 38 - Footnote1 | Table 38 - Footnote2 | 5.5 | ||||||||
| Clindamycin | Campylobacter coli | 10 | 0.25 | 8 | 10.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.0 | Table 38 - Footnote1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10.0 Table 38 - Footnote2 | ||||||||||
| Clindamycin | Campylobacter jejuni | 145 | 0.125 | 0.25 | 3.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.49.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.36.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 | Table 38 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.8 Table 38 - Footnote2 | 0.7 | ||||||
| Erythromycin | Campylobacter coli | 10 | 0.5 | >64 | 10.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.0 | Table 38 - Footnote1 | Table 38 - Footnote2 | 10.0 | |||||||||
| Erythromycin | Campylobacter jejuni | 145 | 0.5 | 1 | 5.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.3 | Table 38 - Footnote1 | Table 38 - Footnote2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.7 | 4.8 | |||||||
| Gentamicin | Campylobacter coli | 10 | 1 | 2 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.0 Table 38 - Footnote1 | Table 38 - Footnote2 | |||||||||||
| Gentamicin | Campylobacter jejuni | 145 | 1 | 1 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.74.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 Table 38 - Footnote1 | Table 38 - Footnote2 | |||||||||||
| Nalidixic acid | Campylobacter coli | 10 | 8 | >64 | 20.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 | Table 38 - Footnote1 | Table 38 - Footnote2 | 20.0 | ||||||||||
| Nalidixic acid | Campylobacter jejuni | 145 | <=4 | 8 | 5.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.55.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.38.6 | Table 38 - Footnote1 | Table 38 - Footnote2 | 5.5 | ||||||||||
| III | Florfenicol | Campylobacter coli | 10 | 1 | 2 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.80.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.0 | Table 38 - Footnote1 | ||||||||||
| Florfenicol | Campylobacter jejuni | 145 | 1 | 1 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.92.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.8 | Table 38 - Footnote1 | |||||||||||
| Tetracycline | Campylobacter coli | 10 | >64 | >64 | 60.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.0 | Table 38 - Footnote1 | Table 38 - Footnote2 | 60.0 | ||||||||
| Tetracycline | Campylobacter jejuni | 145 | 2 | >64 | 48.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.1 | Table 38 - Footnote1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.4 Table 38 - Footnote2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.8 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.19.3 | 24.8 | |||||
| IV | ||||||||||||||||||||
| Antimicrobial | n | Percentiles | % R | Distribution (%) of MICs (µg/mL) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC 50 | MIC 90 | ≤ 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | >256 | ||||
| I | Amoxicillin-clavulanic acid | 157 | <=1 | 16 | 1.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.4 Table 39 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.9 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.6 Table 39 - Footnote2 | 1.3 | |||||||||
| Ceftiofur | 157 | 1 | 1 | 1.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.79.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.0 Table 39 - Footnote1 | Table 39 - Footnote2 | 1.9 | ||||||||||||
| Ceftriaxone | 157 | <=0.25 | <=0.25 | 1.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.98.1 | Table 39 - Footnote1 | Table 39 - Footnote2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.6 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.6 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.6 | |||||||||||
| Ciprofloxacin | 157 | <=0.015 | 0.03 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.80.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.5 Table 39 - Footnote1 | Table 39 - Footnote2 | |||||||||||||
| II | Ampicillin | 157 | <=1 | >32 | 21.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.67.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.3 | Table 39 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.9 Table 39 - Footnote2 | 19.7 | |||||||||
| Azithromycin | 157 | 4 | 8 | 0.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.56.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.5 | 0.6 Table 39 - Footnote2 | ||||||||||||
| Cefoxitin | 157 | 4 | 4 | 1.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.39.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.1 Table 39 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | Table 39 - Footnote2 | 1.9 | ||||||||||
| Gentamicin | 157 | 0.50 | 1 | 1.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.72.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 Table 39 - Footnote1 | Table 39 - Footnote2 | 1.3 | ||||||||||
| Kanamycin | 157 | <=8 | <=8 | 8.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.91.1 | Table 39 - Footnote1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.6 Table 39 - Footnote2 | 8.3 | |||||||||||||
| Nalidixic acid | 157 | 4 | 4 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 | Table 39 - Footnote2 | ||||||||||||
| Streptomycin | 157 | <=32 | >64 | 35.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.3 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.5 Table 39 - Footnote2 | 31.2 | ||||||||||||||
| Trimethoprim-sulfamethoxazole | 157 | <=0.12 | 0.25 | 5.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.74.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9 | Table 39 - Footnote2 | 5.7 | ||||||||||||
| III | Chloramphenicol | 157 | 8 | >32 | 12.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63.1 Table 39 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.3 | Table 39 - Footnote2 | 12.7 | ||||||||||
| Sulfisoxazole | 157 | 64 | >256 | 36.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30.6 | 0.6 | 36.9 Table 39 - Footnote2 | ||||||||||||
| Tetracycline | 157 | <=4 | >32 | 45.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.54.8 Table 39 - Footnote1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.6 Table 39 - Footnote2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.5 | 40.1 | |||||||||||||
| IV | |||||||||||||||||||||
| Antimicrobial | n | Percentiles | % R | Distribution (%) of MICs (µg/mL) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC 50 | MIC 90 | ≤ 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | >256 | ||||
| I | Amoxicillin-clavulanic acid | 184 | 4 | 8 | 1.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29.9 Table 40 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.3 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.6 Table 40 - Footnote2 | ||||||||||
| Ceftiofur | 184 | 0.25 | 0.50 | 1.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.51.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45.7 | Table 40 - Footnote1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.6 Table 40 - Footnote2 | ||||||||||||
| Ceftriaxone | 184 | <=0.25 | <=0.25 | 1.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.5 | Table 40 - Footnote1 | Table 40 - Footnote2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.5 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.1 | |||||||||||
| Ciprofloxacin | 184 | <=0.015 | <=0.015 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.2 | Table 40 - Footnote1 | Table 40 - Footnote2 | |||||||||||||
| II | Ampicillin | 184 | 4 | >32 | 35.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.39.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.1 Table 40 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.5 | Table 40 - Footnote2 | 35.9 | |||||||||
| Azithromycin | 184 | 4 | 8 | 0.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.65.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.4 | 0.5 Table 40 - Footnote2 | |||||||||||
| Cefoxitin | 184 | 4 | 8 | 1.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.59.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.2 Table 40 - Footnote1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.5 Table 40 - Footnote2 | 1.1 | ||||||||||||
| Gentamicin | 184 | 1 | 2 | 1.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.3 | Table 40 - Footnote1 | 1.1 | ||||||||||||
| Kanamycin | 184 | <=8 | >64 | 13.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.85.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.5 Table 40 - Footnote1 | Table 40 - Footnote2 | 13.6 Table 40 - Footnote2 | |||||||||||||
| Nalidixic acid | 184 | 2 | 4 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.78.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.0 | Table 40 - Footnote2 | |||||||||||||
| Streptomycin | 184 | <=32 | >64 | 39.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60.3 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.16.8 Table 40 - Footnote2 | 22.8 | ||||||||||||||
| Trimethoprim-sulfamethoxazole | 184 | <=0.12 | >4 | 13.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.5 | Table 40 - Footnote2 | 13.6 | ||||||||||
| III | Chloramphenicol | 184 | 8 | 32 | 18.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47.3 Table 40 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10.3 Table 40 - Footnote2 | 8.2 | ||||||||||
| Sulfisoxazole | 184 | 32 | >256 | 39.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.1 | 39.1 Table 40 - Footnote2 | |||||||||||||
| Tetracycline | 184 | >32 | >32 | 83.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.8 Table 40 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.5 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.1 Table 40 - Footnote2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.1 | 81.5 | ||||||||||||
| IV | |||||||||||||||||||||
| Antimicrobial | Species | n | Percentiles | % R | Distribution (%) of MICs (µg/mL) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC 50 | MIC 90 | ≤ 0.016 | 0.032 | 0.064 | 0.125 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | >64 | |||||
| I | Ciprofloxacin | Campylobacter coli | 286 | 0.125 | 0.5 | 9.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.8 | Table 41 - Footnote1 | Table 41 - Footnote2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.0 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8.0 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.7 | |||||
| Ciprofloxacin | Campylobacter jejuni | 0 | 0 | 0 | 0.0 | Table 41 - Footnote1 | Table 41 - Footnote2 | |||||||||||||
| Ciprofloxacin | Campylobacter spp. | 1 | 0.25 | 0.25 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0 | Table 41 - Footnote1 | Table 41 - Footnote2 | ||||||||||||
| Telithromycin | Campylobacter coli | 286 | 4 | 16 | 44.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.1 Table 41 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.5 | 44.8 Table 41 - Footnote2 | |||||||
| Telithromycin | Campylobacter jejuni | 0 | 0 | 0 | 0.0 | Table 41 - Footnote1 | Table 41 - Footnote2 | |||||||||||||
| Telithromycin | Campylobacter spp. | 1 | 1 | 1 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0 | Table 41 - Footnote1 | Table 41 - Footnote2 | ||||||||||||
| II | Azithromycin | Campylobacter coli | 286 | >64 | >64 | 52.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.2 | Table 41 - Footnote1 | Table 41 - Footnote2 | 52.8 | |||||||
| Azithromycin | Campylobacter jejuni | 0 | 0 | 0 | 0.0 | Table 41 - Footnote1 | Table 41 - Footnote2 | |||||||||||||
| Azithromycin | Campylobacter spp. | 1 | 0.125 | 0.125 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0 | Table 41 - Footnote1 | Table 41 - Footnote2 | ||||||||||||
| Clindamycin | Campylobacter coli | 286 | 4 | 16 | 44.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.0 Table 41 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.9 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.22.4 Table 41 - Footnote2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.15.4 | 6.3 | |||||
| Clindamycin | Campylobacter jejuni | 0 | 0 | 0 | 0.0 | Table 41 - Footnote1 | Table 41 - Footnote2 | |||||||||||||
| Clindamycin | Campylobacter spp. | 1 | 0.5 | 0.5 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0 | Table 41 - Footnote1 | Table 41 - Footnote2 | Table 41 - Footnote2 | |||||||||||
| Erythromycin | Campylobacter coli | 286 | 64 | >64 | 52.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.0 | Table 41 - Footnote1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.4 Table 41 - Footnote2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.7 | 49.7 | |||||
| Erythromycin | Campylobacter jejuni | 0 | 0 | 0 | 0.0 | Table 41 - Footnote1 | Table 41 - Footnote2 | |||||||||||||
| Erythromycin | Campylobacter spp. | 1 | 1 | 1 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0 | Table 41 - Footnote1 | |||||||||||||
| Gentamicin | Campylobacter coli | 286 | 1 | 2 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.76.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.3 Table 41 - Footnote1 | Table 41 - Footnote2 | |||||||||||
| Gentamicin | Campylobacter jejuni | 0 | 0 | 0 | 0.0 | Table 41 - Footnote1 | Table 41 - Footnote2 | |||||||||||||
| Gentamicin | Campylobacter spp. | 1 | 0.5 | 0.5 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0 | Table 41 - Footnote1 | Table 41 - Footnote2 | ||||||||||||
| Nalidixic acid | Campylobacter coli | 286 | 8 | 32 | 9.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.0 Table 41 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.3 Table 41 - Footnote2 | 9.4 | |||||||||
| Nalidixic acid | Campylobacter jejuni | 0 | 0 | 0 | 0.0 | Table 41 - Footnote1 | Table 41 - Footnote2 | |||||||||||||
| Nalidixic acid | Campylobacter spp. | 1 | >64 | >64 | 100.0 | Table 41 - Footnote1 | Table 41 - Footnote2 | 100.0 | ||||||||||||
| III | Florfenicol | Campylobacter coli | 286 | 1 | 2 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.67.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.3 Table 41 - Footnote1 | |||||||||
| Florfenicol | Campylobacter jejuni | 0 | 0 | 0 | 0.0 | Table 41 - Footnote1 | ||||||||||||||
| Florfenicol | Campylobacter spp. | 1 | 0.5 | 0.5 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0 | Table 41 - Footnote1 | |||||||||||||
| Tetracycline | Campylobacter coli | 286 | 64 | >64 | 75.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 Table 41 - Footnote1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.7 Table 41 - Footnote2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6.3 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.12.2 | 49.3 | ||||
| Tetracycline | Campylobacter jejuni | 0 | 0 | 0 | 0.0 | Table 41 - Footnote1 | Table 41 - Footnote2 | |||||||||||||
| Tetracycline | Campylobacter spp. | 1 | 32 | 32 | 100.0 | Table 41 - Footnote1 | Table 41 - Footnote2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.100.0 | ||||||||||||
| IV | ||||||||||||||||||||
Campylobacter spp. include unidentified species, some of which may be intrinsically resistant to nalidixic acid.
Recovery Results
| CIPARS Component/ Animal species |
Year | Percentage (%) of isolates recovered and number of isolates recovered / number of samples submitted | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Escherichia coli | Salmonella | Campylobacter | Enterococcus | ||||||
| Beef cattle | 2002 | 97% | 76/78 | 1% | 3/78 | ||||
| 2003 | 97% | 155/159 | < 1% | 1/114 | |||||
| 2004 | 98% | 167/170 | |||||||
| 2005 | 97% | 122/126 | 66% | 23/35 | |||||
| 2006 | 100% | 150/150 | 36% | 31/87 | |||||
| 2007 | 99% | 188/190 | 39% | 75/190 | |||||
| 2008 | 97%Table 17 - Footnote b | 176/182 | 71%Table 17 - Footnote a | 129/182 | |||||
| 2009 | 94% | 119/126 | 68% | 86/126 | |||||
| 2010 | 97% | 77/79 | 53%Table 17 - Footnote b | 37/70 | |||||
| 2011 | 99% | 139/141 | 77% | 108/141 | |||||
| 2012 | 99% | 165/166 | 92% | 152/166 | |||||
| Chickens | 2002 | 100% | 40/40 | 13% | 25/195 | ||||
| 2003 | 97% | 150/153 | 16% | 126/803 | |||||
| 2004 | 99% | 130/131 | 16% | 142/893 | |||||
| 2005 | 99% | 218/220 | 18% | 200/1,103 | |||||
| 2006 | 100% | 166/166 | 23% | 187/824 | |||||
| 2007 | 99% | 180/181 | 25% | 204/808 | |||||
| 2008 | 99% | 170/171 | 28% | 234/851 | |||||
| 2009 | 100% | 171/171 | 27% | 230/851 | |||||
| 2010 | 99% | 119/120 | 24% | 142/599 | 19% | 111/599 | |||
| 2011 | 99% | 164/166 | 20% | 140/701 | 17% | 117/696 | |||
| 2012 | 100% | 173/173 | 18%Table 17 - Footnote c | 126/684 | 23% | 155/685 | |||
| Pigs | 2002 | 97% | 38/39 | 27% | 103/385 | ||||
| 2003 | 98% | 153/155 | 28% | 395/1,393 | |||||
| 2004 | 99% | 142/143 | 38% | 270/703 | |||||
| 2005 | 99% | 163/164 | 42% | 212/486 | |||||
| 2006 | 98% | 115/117 | 40% | 145/359 | |||||
| 2007 | 98% | 93/95 | 36% | 105/296 | |||||
| 2008 | 100% | 150/150 | 44% | 151/340 | |||||
| 2009 | 98% | 160/163 | 45% | 147/327 | |||||
| 2010 | 98% | 199/203 | 44% | 182/410 | |||||
| 2011 | 99% | 190/191 | 43% | 165/382 | |||||
| 2012 | 100% | 184/184 | 42% | 157/370 | 78% | 289/370 | |||
|
|||||||||
Grey-shaded areas indicate either: a) isolates recovered from sampling activities outside the scope of CIPARS routine (or "core") surveillance in the specified year (i.e. grey-shaded areas with data) or b) discontinuation or no surveillance activity (i.e. grey-shaded areas with no data).
Page details
- Date modified: